隨著科學的進步,現代醫學逐漸催生出許多用於診斷和治療的新方法。最有名的話題,現在便是在分子基礎上以及幹細胞治療。例如,在糖尿病患的處置當中,最讓人覺得麻煩的,就是糖尿病傷口的治療只有嚴謹地控制感染、補足充分的營養、甚至皮膚移植手術,才能挽救這些病患。然而,糖尿病傷口治療的新進展已包括了各種不同的生物材料、內皮祖細胞或幹細胞,甚至微小RNA的研究和嘗試。我們結合這些新的概念,合併EPC和一個微小RNA(let-7g),將let-7g轉值進入EPC,並用該EPC的培養液來測試對小鼠糖尿病性潰瘍癒合的治療效果。我們發現這些試劑具有好的傷口癒合的效果,這可能提供一種新的方法來處理這些患者的糖尿病難治性潰瘍。此外它也是一個安全的方法,較少有過敏反應,因為細胞來源是自體性的。
Modern medicine was progressively spawned a lot of new methods for diagnosis and therapy, with the advancement of science. Most famous topic now is mainly on the molecular basis and stem cell therapy. For example, in the past, diabetic ulceration is one of the troublesome complications on manage these diabetic patients, and only extreme control of infection, supplement of sufficient nutrition, or even skin graft operation could save these patients. However, new aspects of diabetic wound therapy focused on different biological materials, endothelial progenitor or stem cells, and even microRNA had been studied and tried. We combined these new concepts, with EPC and one microRNA, let-7g, being transfected into the EPCs, and used their cultured condition media to test the therapeutic effects on diabetic ulceration healing of mice. We found good wound healing effects of these reagents, and this may provide a new method to manage those diabetic patient with refractory ulcerations. Besides it is also a safe methods with less allergic reaction because of its autologous.